209286-85-1

Basic information

• Product Name: 5-Chloro-1-(phenylsulfonyl)-4-azaindole
• Synonyms: 5-Chloro-1-(phenylsulfonyl)-4-azaindole;5-CHLORO-1-(PHENYLSULFONYL)-1H-PYRROLO[3,2-B]PYRIDINE
• CAS NO: 209286-85-1
• Molecular Formula: C13H9ClN2O2S
• Molecular Weight: 292.74076
• Mol File: 209286-85-1.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 5-Chloro-1-(phenylsulfonyl)-4-azaindole(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Chloro-1-(phenylsulfonyl)-4-azaindole(209286-85-1)
• EPA Substance Registry System: 5-Chloro-1-(phenylsulfonyl)-4-azaindole(209286-85-1)

Safety Data

• Hazardous Substances Data: 209286-85-1(Hazardous Substances Data)

Upstream product

• 1050501-88-6 2-bromo-6-chloro-pyridin-3-amine 
• 1612287-47-4 6-chloro-2-((trimethylsilyl)ethynyl)pyridin-3-amine 
• 65156-94-7 5-chloro-1H-pyrrolo[3,2-b]pyridine 
• 98-09-9 benzenesulfonyl chloride 

Relevant articles and documents

PYRIDYL OR PYRIMIDYL MTOR KINASE INHIBITORS

The invention relates to compounds or pharmaceutically acceptable salts thereof of formula (I): (I) wherein R1, R2, R3, R4, R4' and R5 are as defined in the description and claims; and comp

6-(MORPHOLIN-4-YL)-PYRIDIN-2-YL-1H-PYRROLO[3,2-B]PYRIDINE DERIVATIVES AS M-TOR INHIBITORS

The invention relates to compounds of formula (I) wherein R1, R2, R3, R4, L and A are as defined in the description and claims, or pharmaceutically acceptable salts thereof having mTOR kinase inhibitor activity. The invention also relates to pharmaceutical compositions including a compound of formula (I) or a pharmaceutically acceptable salt thereof, and to the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof in therapy, including in the treatment of a disease or condition for which an mTOR kinase inhibitor activity is indicated, and in particular the treatment of idiopathic pulmonary fibrosis.

TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS

The present invention relates to tricyclic heterocycles which are inhibitors of BET proteins such as BRD2, BRD3, BRD4, and BRD-t and are useful in the treatment of diseases such as cancer.

New bicyclic compounds as crac channel modulators

The present invention relates to novel compounds which are inhibitors of CRAC channel activity. This invention also relates to pharmaceutical compositions containing them, process for their preparation and their use in therapy.

Design, synthesis, and SAR of cis-1,2-diaminocyclohexane derivatives as potent factor Xa inhibitors. Part I: Exploration of 5-6 fused rings as alternative S1 moieties

A series of cis-1,2-diaminocyclohexane derivatives were synthesized with the aim of optimizing previously disclosed factor Xa (fXa) inhibitors. The exploration of 5-6 fused rings as alternative S1 moieties resulted in two compounds which demonstrated improved solubility and reduced food effect compared to the clinical candidate, compound A. Herein, we describe the synthesis and structure-activity relationship (SAR), together with the physicochemical properties and pharmacokinetic (PK) profiles of some prospective compounds.

Sulfonic acid sulfonylamino n-(heteroaralkyl)-azaheterocyclylamide compounds

The compounds of formula I herein exhibit useful pharmacological activity and accordingly are incorporated into pharmaceutical compositions and used in the treatment of patients suffering from certain medical disorders. More specifically, they are inhibitors of the activity of Factor Xa. The present invention is directed to compounds of formula I, compositions containing compounds of formula I, and their use, for treating a patient suffering from, or subject to, a physiological condition which can be ameliorated by the administration of an inhibitor of the activity of Factor Xa.